The biogen researchers behind the vaccine have won the battle against pharmaceutical companies and their leaders over the years, with several winning patent protection.
And they have won again this year, after Pfizer was defeated in court.
But there are still many challenges ahead for biogen.
For one, it still has to prove that its vaccine is safe and effective in the United States, where it has more than 200 million users.
And, for another, it will have to prove it can make its vaccine more effective, with a longer shelf life and easier to administer.
It’s all a matter of time before the world sees the vaccine, said Dr. William Thompson, chief medical officer at Biogen.
“The vaccine is going to be out in five to 10 years.”
And it will be available to people in a few years, as well, he said.
“We’re a very good company, we’re a great company, and we’re going to win, but it’s going to take time,” he said, adding that Biogen’s vaccine has the potential to have a big impact.
The key to the success of the vaccine is getting the right combination of antibodies, Thompson said.
That combination was what got Pfizer to withdraw its patent application in 2013.
It takes time to make antibodies, so the best antibodies are made from people with high levels of antibodies.
“They are very effective against bacteria,” Thompson said, noting that Pfizer’s antibodies work against several strains of bacteria.
And so, with more than 2.5 million people using the vaccine annually, it’s easy to see why the company’s patent is so important.
It gives Biogen a foothold in the US, and it allows it to market a vaccine that works well in many different types of diseases, Thompson added.
The company’s vaccine works in a variety of conditions.
And for people with some form of cancer, it is particularly effective.
“The vaccine works for people who have lung, liver, pancreatic, or lung-related cancers, and for people that have a variety cancers,” Thompson explained.
The vaccine can also help reduce the risk of infections, especially for people living in areas where the air and water is polluted.
“When we talk about preventing cancer, we want to prevent infections,” he added.
“We’re really focused on preventing disease in our communities.
And our vaccine works with a number of vaccines and has an advantage that’s really unique to us.”
The vaccine also helps to reduce side effects, like diarrhea or fever.
And the vaccine can prevent a range of other cancers, including breast, prostate, pancreatitis, and melanoma.
“It is the only vaccine that has shown this to work,” Thompson told the AP.
“So the only question is whether it’s an effective vaccine.”
The fight for a vaccine against the pandemic isn’t over, however.
Biogen and other vaccine companies have to convince courts that their vaccines are safe, effective, and cost-effective.
The courts are reviewing biogen’s patent application, which has already been approved by the US Food and Drug Administration, and will likely take several months.
And while the vaccine has won, the fight will continue.
Biogenesis is not ready to release the vaccine just yet.
It has yet to make a final decision on how it will distribute it.
It is also up to biogen to show that its vaccines are as effective as the ones Pfizer, AstraZeneca, and other companies have tested.
And it has to show the effectiveness of its vaccines in clinical trials, which it says is proving to be a difficult task.
“At the end of the day, this is not going to go to market in two years,” Thompson noted.
“That’s a big question mark.
So it’s a really tough question to answer.”Read more: